Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 2

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Trust
    Interventions: Behavioral: Community-led discussion
    Sponsors: Old Dominion University
    Recruiting

  2. "Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: 1/10 therapeutic dose; Drug: 1/2 therapeutic dose; Drug: full therapeutic dose; Drug: Patients with a verified diagnosis of COVID-19
    Sponsors: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
    Not yet recruiting

  3. Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: COVID - 19
    Interventions: Drug: Ratutrelvir (83-0060) non-randomised; Drug: Paxlovid; Drug: Ratutrelvir (83-0060)
    Sponsors: Traws Pharma, Inc.
    Not yet recruiting

  4. Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Long COVID Companion App

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Other: No Intervention: Observational Cohort
    Sponsors: Luxembourg Institute of Health
    Not yet recruiting

  5. Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Brain Fog; Long COVID; Transcranial Ultrasound Stimulation
    Interventions: Device: sham transcranial ultrasound stimulation; Device: real transcranial ultrasound stimulation
    Sponsors: Xuanwu Hospital, Beijing
    Recruiting

  6. Hepatitis B Virus Reactivation in COVID-19

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 Pneumonia; Hypoxemia; Hepatitis B
    Interventions: Diagnostic Test: Hepatitis B virus infection
    Sponsors: University Medical Centre Ljubljana
    Completed

  7. Impact of Covid-19 on Syphilis

    Tue, 02 Sep 2025 04:00:00 -0000

    Conditions: Syphilis; COVID - 19; HIV (Human Immunodeficiency Virus); Retrospective Studies
    Interventions: Other: Patients diagnosed with syphilis
    Sponsors: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
    Active, not recruiting

  8. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia
    Sponsors: National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting

  9. Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Dimolegin
    Sponsors: Avexima Diol LLC
    Completed

  10. A Study to Examine Anktiva for the Treatment of COVID-19.

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Long COVID; Long COVID Syndrome; Long Covid 19
    Interventions: Drug: Anktiva
    Sponsors: ImmunityBio, Inc.
    Recruiting

  11. Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: STX-S
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  12. Neutralizing Power of Serum Antibodies - 2

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; SARS-CoV-2 Viraemia; Monkey Pox; Vaccination; Serum; Mucosal Immunity
    Interventions: Other: Sample collection (blood and optional nasal swab)
    Sponsors: Centre Hospitalier Régional d'Orléans
    Recruiting

  13. Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: PASC Post Acute Sequelae of COVID-19
    Interventions: Drug: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static); Drug: A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only); Drug: B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static); Drug: B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
    Sponsors: University of California, Davis; National Institute of Allergy and Infectious Diseases (NIAID); University of California, San Francisco
    Not yet recruiting

  14. Effectiveness of Functional Respiratory Muscle Training in Post-COVID-19 Syndrome

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Post COVID-19 Syndrome; Functional Inspiratory Muscle Training; Core Stabilization
    Interventions: Other: Core Stabilization; Other: Functional Inspiratory Muscle Training (IMT)
    Sponsors: Hacettepe University
    Not yet recruiting

  15. Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Acute Respiratory Distress Syndrome Due to COVID-19; Pregnancy Related
    Sponsors: Charite University, Berlin, Germany
    Recruiting

  16. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir
    Sponsors: Pfizer
    Recruiting

  17. Heat thErapy And mobiLity in COVID-19 Survivors

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: Heat therapy; Behavioral: Sham Control; Behavioral: Walking
    Sponsors: University of Nebraska; National Institute on Aging (NIA)
    Not yet recruiting

  18. A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection; COVID-19; COVID-19 Infection; Coronavirus Disease 2019 (COVID-19); COVID-19 (Coronavirus Disease 2019); COVID-19 Vaccination; COVID-19 Vaccines; SARS-CoV-2 Infection, COVID19; SARS-CoV-2 Infection, COVID-19
    Interventions: Drug: BNT162b2
    Sponsors: Pfizer
    Active, not recruiting

  19. PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Long COVID; Post Acute Sequelae of COVID-19
    Interventions: Drug: 11C-PS13
    Sponsors: National Institute of Mental Health (NIMH)
    Recruiting

  20. Evaluation of the Gambling Habits of Adolescents and Young Adults Post-COVID-19 and Implementation of a Digital Escape Room Intervention for Preventing Gambling in High School Students

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Mental Health
    Interventions: Behavioral: GAMBL-OUT program
    Sponsors: Hospital Miguel Servet
    Recruiting

  21. NE3107 in Adults With Neurological Symptoms of Long COVID

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Drug: NE3107; Drug: Placebo
    Sponsors: BioVie Inc.
    Recruiting

  22. EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID - 19
    Interventions: Drug: Colchicine 0.5 MG Oral Tablet
    Sponsors: Zaeema Kanwal
    Completed

  23. Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Immunology; Allergy; Genetic Diseases; Infectious Diseases
    Interventions: Other: blood sample
    Sponsors: Institut National de la Santé Et de la Recherche Médicale, France
    Recruiting

  24. Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated; Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
    Sponsors: Pfizer; CVS Caremark
    Active, not recruiting

  25. Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Immunocompromised Patients; SARS-CoV-2 Disease
    Interventions: Other: Collection of data from the patient's medical file
    Sponsors: Assistance Publique - Hôpitaux de Paris; URC Necker Cochin, France
    Not yet recruiting

  26. A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 1; Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 2; Combination Product: Flu Seasonal mRNA; Combination Product: SARS-CoV-2 mRNA Dose 1; Combination Product: SARS-CoV-2 mRNA Dose 2; Combination Product: Licensed Flu Seasonal; Combination Product: Licensed COVID-19 mRNA; Drug: Placebo
    Sponsors: GlaxoSmithKline
    Completed

  27. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection
    Interventions: Drug: ibuzatrelvir; Drug: placebo
    Sponsors: Pfizer
    Recruiting

  28. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Recruiting

  29. Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Trust
    Interventions: Behavioral: Community-led discussion
    Sponsors: Old Dominion University
    Completed

  30. Probiotic Use for Recovery Enhancement From Long COVID-19

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome
    Interventions: Drug: Probiotic Agent; Other: Placebo
    Sponsors: Rush University Medical Center
    Active, not recruiting

  31. Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 Vaccination
    Interventions: Biological: Bretovameran
    Sponsors: Pfizer
    Active, not recruiting

  32. The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19

    Tue, 02 Sep 2025 04:00:00 -0000

    Conditions: Pulmonary Complications; Cardiovascular Complications; Renal Complications; COVID-19
    Interventions: Other: Blood samples; Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

  33. Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Birth Outcomes; Safety; Adverse Event Following Immunization
    Interventions: Biological: mRNA COVID-19 vaccine; Biological: IIV4 (quadrivalent inactivated influenza vaccine)
    Sponsors: Duke University
    Active, not recruiting

  34. Cognitive Muscular Therapy for Patients With Long-COVID and Breathing Pattern Disorder

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Long COVID; Respiratory Disease
    Interventions: Behavioral: Cognitive Muscular Therapy; Behavioral: Breathing visualisation
    Sponsors: University of Salford
    Active, not recruiting

  35. SARS-CoV-2 Safety Study for the Treatment of COVID-19

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Drug: HIV; Drug: Malignant Neoplasms Safety Study for the Treatment of Neoplasms
    Sponsors: DHA Coffee Co., Ltd
    Withdrawn

  36. Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: MPV/S-2P
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

  37. Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19 Vaccines
    Interventions: Biological: Vaccination
    Sponsors: Pfizer
    Completed

  38. Telecommunication Technology-based Online Survey

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Risk Factors; Polypharmacy; Drug Interactions; Self Medication; COVID-19
    Interventions: Other: Online Survey; Diagnostic Test: Genetic Testing
    Sponsors: Tomsk National Research Medical Center of the Russian Academy of Sciences
    Recruiting

  39. PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: Vaccine Messaging; Behavioral: Vaccine Acceptance Question
    Sponsors: University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer; Duke University; Baylor College of Medicine; Thomas Jefferson University
    Completed

  40. Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: Misinformation; Vaccine Hesitancy; Anxiety; Depression; COVID-19
    Interventions: Behavioral: Attitudinal inoculation; Behavioral: Cognitive-behavioral therapy-informed intervention; Behavioral: Conventional public health messaging
    Sponsors: City University of New York, School of Public Health; University of North Carolina, Chapel Hill; National Institute of Mental Health (NIMH)
    Completed

  41. Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Fever After Vaccination; Fever; Seizures Fever
    Interventions: Biological: mRNA COVID-19 Vaccine; Biological: Routine Childhood Vaccinations
    Sponsors: Duke University; Kaiser Permanente; Columbia University; Children's Hospital Medical Center, Cincinnati; Centers for Disease Control and Prevention
    Completed

  42. Cereset Research Long-Term Healthcare Worker Study

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Stress; Anxiety; Autonomic Dysregulation; Acoustic Stimulation; Hyperarousal; Health Personnel
    Interventions: Device: Cereset Research
    Sponsors: Wake Forest University Health Sciences; The Susanne Marcus Collins Foundation, Inc.
    Completed

  43. Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; Post-Acute COVID-19 Syndrome
    Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine
    Sponsors: Pfizer
    Active, not recruiting

  44. Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Cardiac Arrest; COVID-19; Coronavirus
    Interventions: Device: Aerosol box
    Sponsors: KidSIM Simulation Program; Canadian Institutes of Health Research (CIHR)
    Recruiting

  45. Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: abatacept infusion; Drug: Placebo group
    Sponsors: University of Minnesota
    Completed

  46. Complementary Self-help Strategies for Patients With Post-COVID-19 Syndrome

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Post-COVID-19 Syndrome
    Interventions: Behavioral: Complementary self-help strategies in addition to treatment as usual; Other: Treatment as usual
    Sponsors: Universität Duisburg-Essen
    Active, not recruiting

  47. Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: ADVANCE Steering Committee interventions
    Sponsors: Yale University; National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting

  48. Teletechnology-assisted Home-based Exercise Program for Severe COVID-19

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Telerehabilitation
    Interventions: Behavioral: Teletechnology-assisted home-based pulmonary rehabilitation
    Sponsors: National Taiwan University Hospital
    Completed

  49. Use of E-health Based Exercise Intervention After COVID-19

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: Exercise training using an e-health tool
    Sponsors: Norwegian University of Science and Technology; University of Oslo
    Completed

  50. Hormonal Contributors to COVID-19 Infection (COV-ENDO)

    Tue, 02 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 Pandemic; Endocrine System Diseases
    Interventions: Other: blood testing
    Sponsors: Istituto Auxologico Italiano
    Completed

  51. Fatigability in Long COVID-19

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: Minimal-Dose Home-Based Resistance Exercise
    Sponsors: VA Office of Research and Development
    Active, not recruiting

  52. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Viral Lung Infection and Acute Respiratory Failure
    Interventions: Drug: Tozorakimab; Drug: Placebo
    Sponsors: AstraZeneca
    Recruiting

  53. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Shionogi Protease Inhibitor (S-217622); Drug: placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

  54. Paxlovid for Treatment of Long Covid

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Post-acute Sequelae of SARS-CoV-2 Infection; Long COVID
    Interventions: Drug: Nirmatrelvir; Drug: Placebo; Drug: Ritonavir
    Sponsors: Stanford University; Pfizer
    Completed

  55. VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Immunization; Infection; Pregnancy Related; COVID-19
    Interventions: Behavioral: VAX-MOM COVID-19 Intervention; Other: Standard of Care
    Sponsors: University of Rochester; Centers for Disease Control and Prevention; University of California, Los Angeles
    Completed

  56. The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Rheumatic Diseases
    Interventions: Biological: Hepatitis A vaccine; Biological: Diphtheria, pertussis, and tetanus booster vaccine
    Sponsors: Oregon Health and Science University
    Active, not recruiting

  57. A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19
    Interventions: Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
    Sponsors: BioNTech SE; Pfizer
    Recruiting

  58. Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: AD17002 + Formulation buffer; Biological: Placebo
    Sponsors: Advagene Biopharma Co. Ltd.; Gadjah Mada University
    Terminated

  59. Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Post COVID-19 Condition
    Interventions: Behavioral: Personalized multidisciplinary day-hospital intervention
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Completed

  60. Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Heart Disease
    Sponsors: National Human Genome Research Institute (NHGRI)
    Completed

  61. Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: pulmonary vascular dysfunction; Other: pulmonary vascular function
    Sponsors: University of Giessen
    Active, not recruiting

  62. Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Systemic Inflammation; Neuroinflammation; Microvascular Thrombosis
    Interventions: Drug: IV normal saline; Drug: IV immunoglobulin
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Enrolling by invitation

  63. A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Myocarditis
    Interventions: Diagnostic Test: Cardiac Imaging
    Sponsors: Pfizer; Carelon Research; National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  64. Respiratory Virus Sampling and Repository

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: Influenza; COVID-19
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  65. A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Drug: nirmatrelvir / ritonavir
    Sponsors: Pfizer
    Completed

  66. Impact of the COVID-19 Pandemic on the Health Status of People Aged 75 and Over and Their Caregivers

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Aging; SARS-CoV-2 Infection; Caregivers; Frailty; Burden, Caregiver
    Interventions: Other: Exposure SARS-CoV-2 Infection
    Sponsors: Gerencia de Atención Primaria, Madrid; Instituto de Salud Carlos III; Hospital del Mar Research Institute (IMIM); Fundación para la Investigación e Innovación Biosanitaria de la Comunidad de Madrid
    Completed

  67. Improving Post-acute Stroke Follow-up Care by Adopting Telecare Consultations in a Nurse-led Clinic

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Stroke
    Interventions: Procedure: Telecare consultation; Procedure: Usual face-to-face consultation
    Sponsors: The Hong Kong Polytechnic University; The Queen Elizabeth Hospital
    Recruiting

  68. A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Coronavirus Disease 2019; Influenza
    Interventions: Biological: COVID-19 Vaccine
    Sponsors: Pfizer; CVS Caremark
    Recruiting

  69. Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Health Personnel Attitude; Health Knowledge, Attitudes, Practice
    Interventions: Behavioral: Tailored HPV Education and Professional Skills Intervention Group; Behavioral: General HPV Education and Communication Skills Control Group
    Sponsors: University of Texas, El Paso; National Institute on Minority Health and Health Disparities (NIMHD); Burrell College of Osteopathic Medicine
    Completed

  70. SARS-CoV-2 Infection in COVID-19 Vaccinated Patients

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Diagnostic Test: COVID-19 vaccinated people
    Sponsors: Hospices Civils de Lyon
    Completed

  71. Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: AntiCov-220; Drug: AntiCov-220 (placebo)
    Sponsors: Nguyen Thi Trieu, MD
    Completed

  72. A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Upper Respiratory Infection; Lower Respiratory Infection
    Interventions: Device: Fitbit; Device: Douglas Bag; Device: Periflux 6000 EPOS; Device: BIOPAC; Device: Flowmet; Device: NIRS
    Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Completed

  73. Korea Comirnaty Post-marketing Surveillance

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: COVID-19; Vaccines; Adverse Effects; SARS-CoV-2; Safety
    Interventions: Biological: Tozinameran 12 Years of age and older; Biological: Tozinameran 5 to 11 Years of age; Biological: Tozinameran 6 months to 4 years of age; Biological: Riltozinameran 12 Years of age and older; Biological: Famtozinameran 12 Years of age and older; Biological: Famtozinameran 5 to 11 Years of age; Biological: Raxtozinameran 12 years of age and older; Biological: Raxtozinameran 6 months to 4 years of age
    Sponsors: Pfizer
    Active, not recruiting

  74. Effects of Inspiratory Muscle Training After Covid-19 (ReCOV)

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Covid-19; Respiratory Complication; Post-Acute Covid-19 Syndrome
    Interventions: Other: Inspiratory muscle training (IMT); Other: Physical exercise
    Sponsors: Karolinska Institutet; Karolinska University Hospital
    Completed

  75. A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Parenting; Covid19
    Interventions: Behavioral: CARE Program and Valera Application with care manager functionality; Behavioral: Valera Application with care manager functionality; Behavioral: CARE Program; Behavioral: Valera Application; Behavioral: CARE Program and Valera Application
    Sponsors: Albert Einstein College of Medicine; National Institute of Mental Health (NIMH); University of Miami
    Recruiting

  76. The Effect of Virtual Reality Exercises on Patients With Post-COVID-19 Condition

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Virtual Realty Exercises; Other: conventional exercises
    Sponsors: Cumhuriyet University
    Completed

  77. Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Influenza Immunization; Healthy Volunteers
    Interventions: Biological: Quadrivalent Inactivated Influenza High Dose; Biological: COVID-19 mRNA Vaccine (nucleoside modified)
    Sponsors: Sanofi Pasteur, a Sanofi Company
    Completed

  78. RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: mQFPD; Drug: organic brown rice
    Sponsors: University of California, San Diego
    Completed

  79. Iron and COVID-19 Vaccine Response

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Iron Deficiency Anemia; Vaccine Response Impaired; COVID-19 Vaccine; Iron Deficiency Anemia Treatment
    Interventions: Dietary Supplement: Ferinject
    Sponsors: Jomo Kenyatta University of Agriculture and Technology
    Completed

  80. COVID-19 Patient Cohort: Retinal Damage in Non-invasive Retinal Imaging (OCTA)

    Tue, 02 Sep 2025 04:00:00 -0000

    Conditions: Covid19; Retina Injury
    Sponsors: Centre Hospitalier Intercommunal Creteil
    Terminated

  81. Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Autoimmune Diseases; Inflammatory Disorder
    Interventions: Biological: Blood sample
    Sponsors: Assistance Publique - Hôpitaux de Paris; Immunov; URC Necker Cochin, France
    Terminated

  82. Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC); Other: Placebo
    Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre
    Terminated

  83. COVID-19 And Lingering Symptoms In Primary Care Patients

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Covid19; Symptoms and Signs
    Sponsors: Katarina Hedin; Research Unit for General Practice in Aalborg; Utrecht University; National University of Ireland, Galway, Ireland; Region Jönköping County
    Completed

  84. Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Diagnostic Test: Serological test for the detection of IgG anti-SARS-CoV-2
    Sponsors: Institut National de la Santé Et de la Recherche Médicale, France
    Completed

  85. Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

    Wed, 10 Sep 2025 04:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome; ME/CFS; Rheumatic Arthritis; Juvenile Rheumatoid Arthritis (JRA); Psoriatic Arthritis (PsA); Ankylosing Spondylitis (AS); Autoimmune Encephalitis; Bipolar Disorder (BPD); Celiac Disease; Celiac Disease in Children; Chronic Lyme Disease; Post-treatment Lyme Disease Syndrome; Crohn's Disease; Dysautonomia; Anorexia Nervosa; Bulimia Nervosa; ARFID; Avoidant / Restrictive Food Intake Disorder; Ehlers Danlos Syndrome; Endometriosis; Fibromyalgia (FM); Long COVID; Lupus; Major Depression; Migraines; Mast Cell Activation Syndrome; Multiple Sclerosis; Myalgic Encephalomyelitis (ME); Myasthenia Gravis, Generalized; Myasthenia Gravis in Children; Narcolepsy; Obsessive Compulsive Disorder (OCD); PANDAS; Pediatric Acute-onset Neuropsychiatric Syndrome (PANS); POTS - Postural Orthostatic Tachycardia Syndrome; General Anxiety Disorder, Social Anxiety Disorder; PTSD - Post Traumatic Stress Disorder; Psoriasis; Traumatic Brain Injury; Tourette's Syndrome; Inflammatory Bowel Disease (IBD); Autoimmune Diseases; Neurological Diseases or Conditions; Psychiatric Disorder; Sjogren's Syndrome; Ulcerative Colitis and Crohn's Disease
    Sponsors: Brain Inflammation Collaborative; Solve ME/CFS Initiative; Care Evolution; Columbia University
    Recruiting

  86. Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: SARS-CoV-2 mRNA vaccine formulation 1; Biological: SARS-CoV-2 mRNA vaccine formulation 2; Biological: SARS-CoV-2 mRNA vaccine formulation 3; Biological: Placebo (0.9% normal saline)
    Sponsors: Sanofi Pasteur, a Sanofi Company
    Terminated

  87. Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Influenza; COVID-19
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  88. Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Intensive Care Units; ARDS, Human; Covid19
    Interventions: Other: Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3); Other: Usual treatments in intensive care unit according to the current state of knowledge
    Sponsors: Hospices Civils de Lyon
    Completed

  89. AGILE (Early Phase Platform Trial for COVID-19)

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: CST-2: EIDD-2801; Drug: CST-2: Placebo; Drug: Nitazoxanide; Drug: VIR-7832; Drug: VIR-7831; Drug: CST-5: Placebo; Drug: Favipiravir; Drug: Molnupiravir; Drug: Paxlovid; Drug: ALG-097558; Drug: ALG-097558 and Remdesivir; Drug: NHS standard of care as per COVID-19 treatment guidelines
    Sponsors: University of Liverpool; Liverpool School of Tropical Medicine; Royal Liverpool University Hospital; University of Cambridge
    Recruiting

  90. Hearts of Athletes

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Cardiac Involvement With COVID-19
    Sponsors: Duke University; The Joel Cornette Foundation
    Recruiting

  91. GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Biological: GLS-5310; Biological: Placebo
    Sponsors: GeneOne Life Science, Inc.
    Completed

  92. COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)

    Fri, 05 Sep 2025 04:00:00 -0000

    Conditions: Infection Viral
    Interventions: Other: Collection of blood, salivary and nasopharyngeal samples.
    Sponsors: Hospices Civils de Lyon
    Completed

  93. French Cohort of COVID-19 Patients With Post-intensive Care Syndrome

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Behavioral: Post-intensive Care unit syndrome; Other: Spatiotemporal measurements of walking
    Sponsors: Assistance Publique - Hôpitaux de Paris; URC Necker Cochin, France
    Completed

  94. Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Post-Coronavirus Disease 19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  95. Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: COVID-19 Infection; COVID-19-Associated Acute Respiratory Distress Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions: Other: Best Practice; Biological: Mesenchymal Stem Cell
    Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
    Recruiting

  96. Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19

    Thu, 11 Sep 2025 04:00:00 -0000

    Conditions: Mindfulness; COVID-19; Healthcare Worker
    Interventions: Other: Mindfulness based intervention
    Sponsors: Instituto de Investigación Hospital Universitario La Paz; Hospital Universitario La Paz
    Completed

  97. Serological Surveillance for COVID-19 in Central North Carolina

    Fri, 12 Sep 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Completed

  98. Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: Infectious Disease; Cancer; Coronavirus Infection
    Interventions: Diagnostic Test: Throat/nose swabs; Diagnostic Test: Saliva collection; Diagnostic Test: Blood collection
    Sponsors: Royal Marsden NHS Foundation Trust; St George's, University of London; Mologic Ltd; The Royal Marsden Cancer Charity; National Institute for Health Research Biomedical Research Centre
    Completed

  99. Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Sars-CoV2; Serum; Disease
    Interventions: Other: PRO-SERO-COV
    Sponsors: Institut Bergonié
    Completed

  100. TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Healthcare Workers; COVID-19; SARS-CoV 2
    Interventions: Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet; Drug: Placebo
    Sponsors: Hospital Italiano de Buenos Aires; Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)
    Terminated

  101. Investigating a Vaccine Against COVID-19

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Coronavirus
    Interventions: Biological: ChAdOx1 nCoV-19 (Abs 260); Biological: MenACWY vaccine; Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost; Biological: Two dose MenACWY vaccine; Biological: ChAdOx1 nCoV-19 (qPCR); Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost; Biological: Two dose MenACWY vaccine min. 4 weeks apart; Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL; Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL
    Sponsors: University of Oxford
    Completed

  102. Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Patients Undergoing Cardiac or Thoracic Surgery
    Interventions: Other: No intervention
    Sponsors: Nantes University Hospital
    Recruiting

  103. Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis

    Tue, 09 Sep 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Biological: Biological sampling
    Sponsors: Luxembourg Institute of Health; Centre Hospitalier du Luxembourg; Hopitaux Robert Schuman (Luxembourg); Laboratoire National de Santé (Luxembourg); University of Luxembourg
    Completed

  104. A Study of a Candidate COVID-19 Vaccine (COV001)

    Wed, 03 Sep 2025 04:00:00 -0000

    Conditions: Coronavirus
    Interventions: Biological: ChAdOx1 nCoV-19; Biological: MenACWY; Biological: ChAdOx1 nCoV-19 full boost; Biological: ChAdOx1 nCoV-19 half boost; Biological: MenACWY boost; Drug: Paracetamol; Biological: ChAdOx1 nCoV-19 0.5mL boost; Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV); Biological: ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)
    Sponsors: University of Oxford
    Completed

  105. COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus

    Tue, 02 Sep 2025 04:00:00 -0000

    Conditions: Infection Viral
    Interventions: Other: nosocomial infection/hospital acquired infection
    Sponsors: Hospices Civils de Lyon
    Completed

  106. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)

    Mon, 08 Sep 2025 04:00:00 -0000

    Conditions: Acute Respiratory Distress Syndrome
    Interventions: Biological: Human umbilical cord derived CD362 enriched MSCs; Biological: Placebo (Plasma-Lyte 148)
    Sponsors: Belfast Health and Social Care Trust; Queen's University, Belfast; Northern Ireland Clinical Trials Unit; NHS Blood and Transplant
    Active, not recruiting

  107. Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

    Thu, 04 Sep 2025 04:00:00 -0000

    Conditions: HIV; Cardiovascular Diseases
    Interventions: Drug: Pitavastatin; Drug: Placebo
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute (NHLBI); Kowa Pharmaceuticals America, Inc.; Gilead Sciences; Massachusetts General Hospital; NEAT ID Foundation
    Completed